ClinicalTrials.gg
CompletedNCT03715205Updated Aug 29, 2025Results posted

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

A Phase 4 interventional study of Pembrolizumab in Carcinoma, Non-Small-Cell Lung and Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 8 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
41st of 127
150 · median 65
Started
2019
with 7 others
Phase 4
Only one
of the 127
Registered
58th of 127
by date
Lead sponsor
27 of 127
Merck Sharp & Dohme LLC

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 41st largest by enrollment, is one of 8 that started in 2019, is the only one in phase 4, and was the 58th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed cell death ligand 1 [PD-L1] ≥50%) or have experienced disease progression after a platinum-containing systemic therapy (PD-L1 ≥1%).

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Melanoma

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Melanoma Participant:

  • Has a confirmed diagnosis of unresectable Stage III or melanoma (Stage IV) not amenable to local therapy
  • Has received no more than 1 line of prior systemic therapy for unresectable Stage III or Stage IV melanoma including mitogen activated protein kinase inhibitors
  • Has a Lactate Dehydrogenase (LDH) ≤1.5 times

NSCLC Participant- Treatment:

  • Has a histologically or cytologically confirmed diagnosis of Stage IV NSCLC
  • Has a tumor that demonstrate strong expression (PD-L1 ≥50%)
  • Do not have an EGFR sensitizing mutation AND are anaplastic lymphoma kinase (ALK) translocation negative
  • Has received no systemic anti-cancer therapy for their metastatic NSCLC

NSCLC Participant-Second Line Treatment and Beyond:

  • Has a histologically or cytologically confirmed diagnosis of stage IIIB//IIIC/IV (including any future updates to the American Joint Committee on Cancer [AJCC] guideline) or recurrent NSCLC
  • Has a tumor that expresses programmed cell death ligand 1 (PD-L1) ≥1%
  • Has received prior treatment with at least two cycles of a platinum-containing doublet for Stage IIIB/IV or recurrent disease
  • Has received an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (either erlotinib, gefitinib, or afatinib) if they have an EGFR sensitizing mutation
  • Has received crizotinib if they have an ALK translocation

NSCLC participants must also meet the following requirements:

  • Have a of at ≥3 months
  • Provide a formalin fixed tumor tissue sample for PD-L1 biomarker analysis from a recent of a tumor lesion not previously irradiated; For first line, biopsies obtained PRIOR to the administration of any systemic therapy administered for the treatment of a tumor (such as /adjuvant/definitive therapy) will not be permitted for analysis. For second line treatment and beyond, no systemic antineoplastic therapy may be administered between the PD-L1 biopsy and initiating study medication
  • Have documented evidence of the EGFR mutation status or ALK translocation status. If unable to provide documentation of these molecular changes, formalin-fixed paraffin-embedded tumor tissue of any age should be submitted for testing
  • Have per Version 1.1 (RECIST 1.1) as assessed by the local site investigator/radiologist
  • Have an (ECOG) performance status of 0 to 1
  • Women of (WOCP) must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of trial treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • WOCP must be willing to use an adequate method of for the course of the study through 120 days after the last dose of trial treatment
  • Men of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy

Exclusion criteria

Exclusion Criteria:

  • For NSCLC Participant only: Has a tumor specimen that is not evaluable for expression by the laboratory
  • Is currently participating in or has participated in a trial of an agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment
  • Has received prior therapy with an anti- programmed cell death 1 (PD-1), anti-PD-L1, or anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another T-cell receptor (i.e., cytotoxic T-lymphocyte antigen-4 [CTLA-4], OX-40, CD137) or has previously participated in a clinical trial for pembrolizumab (MK-3475)
  • Has received prior anti-cancer therapy including investigational agent or device within 4 weeks, or completed palliative radiotherapy within 7 days, prior to enrollment
  • Has recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline
  • Has recovered adequately from the toxicity and/or complications from major surgery prior to starting trial treatment
  • Is expected to require any other form of antineoplastic therapy while participating in the trial
  • Is on systemic therapy within 7 days before the planned date for first dose of treatment or any other form of medication
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (exceeding 10 mg daily dose of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatment
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has a known additional that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical cancer in situ, breast carcinoma) that have undergone potentially curative therapy
  • Has had an allogeneic tissue/solid organ transplant
  • Has a history of or current radiographically detectable central nervous system and/or carcinomatous meningitis
  • Has a severe (≥ Grade 3) to any in pembrolizumab
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy including known history of active tuberculosis (Bacillus tuberculosis)
  • Has a known history of (HIV) infection
  • Has a known history of or is positive for (hepatitis B surface antigen [HbsAg] reactive) or (HCV) ribonucleic acid (RNA) [qualitative] is detected
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
  • If participant received prior radiation therapy to a symptomatic metastatic lesion, has recovered to (CTCAE) Version 4.0 Grade 1 or Grade 0 AEs due to radiation therapy
  • Is a regular user of any illicit drug or has a recent history (within the last 3 months) of substance abuse including alcohol
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment
  • Has received a within 30 days before the first dose of trial treatment
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Pembrolizumab 200 mg IV Q3W

    Participants with melanoma or NSCLC receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.

    Drug: Pembrolizumab

Interventions

  • Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

    Also known as: KEYTRUDA®, MK-3475

06

What researchers measure

Primary outcomes

  1. Number of Participants With an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. The number of participants with an AE was reported.

    Time frame: Up to approximately 66.5 months

  2. Number of Participants With a Serious Adverse Event (SAE)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. An SAE was any adverse event occurring at any dose or during any use of Sponsor's product that resulted in death; was life threatening; resulted in persistent or significant disability/incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly/birth defect; was another important medical event. The number of participants with an SAE was reported.

    Time frame: Up to approximately 66.5 months

  3. Number of Participants With a Drug-Related AE

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A drug-related AE was defined as an AE that was determined by the investigator to be possibly, probably, or definitely related to drug. The number of participants with a drug-related AE was reported.

    Time frame: Up to approximately 66.5 months

  4. Number of Participants With a Drug-Related SAE

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An SAE was any AE occurring at any dose or during any use of Sponsor's product that resulted in death; was life threatening; resulted in persistent or significant disability/incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly/birth defect; was another important medical event. A drug-related SAE was defined as an SAE that was determined by the investigator to be possibly, probably, or definitely related to drug. The number of participants with a drug-related SAE was reported.

    Time frame: Up to approximately 66.5 months

  5. Number of Participants Who Discontinued Study Drug Due to an AE

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. The number of participants who discontinued study drug due to an AE was reported

    Time frame: Up to approximately 26 months

Other outcomes

  1. Number of Participants With an Adverse Event of Special Interest (AEOSI)

    An AEOSI was defined as an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. Pembrolizumab AEOSIs included immune-mediated events (pneumonitis, colitis, hepatitis, nephritis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism, thyroiditis, type 1 diabetes mellitus, severe skin reactions including Stevens-Johnson Syndrome \[SJS\] and Toxic Epidermal Necrolysis \[TEN\], uveitis, pancreatitis, myositis, Guillain-Barre Syndrome, myocarditis, encephalitis, sarcoidosis, myasthenic syndrome, myelitis, vasculitis, cholangitis sclerosing, hypoparathyroidism, arthritis, haemophagocytic lymphohistiocytosis, optic neuritis, gastritis, haemolytic anaemia, exocrine pancreatic insufficiency, pericarditis) and infusion reactions. The number of participants with an AEOSI was reported.

    Time frame: Up to approximately 66.5 months

07

Results

Posted Aug 29, 2025

Participant flow

Participants with unresectable or metastatic melanoma, or Non-small Cell Lung Cancer (NSCLC) who were either treatment naïve or had disease progression after prior treatment, were recruited to the study.

Participant flow — Overall Study
MilestonePembrolizumab 200 mg IV Q3W
Started150
Completed16
Not completed134
Withdrew: Death13
Withdrew: Lost to follow-up2
Withdrew: Physician decision93
Withdrew: Withdrawal by subject26

Outcome measures

PrimaryNumber of Participants With an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. The number of participants with an AE was reported.

Time frame:
Up to approximately 66.5 months
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsPembrolizumab 200 mg IV Q3W
Number of Participants With an Adverse Event (AE)131
PrimaryNumber of Participants With a Serious Adverse Event (SAE)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. An SAE was any adverse event occurring at any dose or during any use of Sponsor's product that resulted in death; was life threatening; resulted in persistent or significant disability/incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly/birth defect; was another important medical event. The number of participants with an SAE was reported.

Time frame:
Up to approximately 66.5 months
Reported as:
Count of participants · Participants
Number of Participants With a Serious Adverse Event (SAE)
ParticipantsPembrolizumab 200 mg IV Q3W
Number of Participants With a Serious Adverse Event (SAE)31
PrimaryNumber of Participants With a Drug-Related AE

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A drug-related AE was defined as an AE that was determined by the investigator to be possibly, probably, or definitely related to drug. The number of participants with a drug-related AE was reported.

Time frame:
Up to approximately 66.5 months
Reported as:
Count of participants · Participants
Number of Participants With a Drug-Related AE
ParticipantsPembrolizumab 200 mg IV Q3W
Number of Participants With a Drug-Related AE61
PrimaryNumber of Participants With a Drug-Related SAE

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An SAE was any AE occurring at any dose or during any use of Sponsor's product that resulted in death; was life threatening; resulted in persistent or significant disability/incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly/birth defect; was another important medical event. A drug-related SAE was defined as an SAE that was determined by the investigator to be possibly, probably, or definitely related to drug. The number of participants with a drug-related SAE was reported.

Time frame:
Up to approximately 66.5 months
Reported as:
Count of participants · Participants
Number of Participants With a Drug-Related SAE
ParticipantsPembrolizumab 200 mg IV Q3W
Number of Participants With a Drug-Related SAE10
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. The number of participants who discontinued study drug due to an AE was reported

Time frame:
Up to approximately 26 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsPembrolizumab 200 mg IV Q3W
Number of Participants Who Discontinued Study Drug Due to an AE11
Other pre-specifiedNumber of Participants With an Adverse Event of Special Interest (AEOSI)

An AEOSI was defined as an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. Pembrolizumab AEOSIs included immune-mediated events (pneumonitis, colitis, hepatitis, nephritis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism, thyroiditis, type 1 diabetes mellitus, severe skin reactions including Stevens-Johnson Syndrome \[SJS\] and Toxic Epidermal Necrolysis \[TEN\], uveitis, pancreatitis, myositis, Guillain-Barre Syndrome, myocarditis, encephalitis, sarcoidosis, myasthenic syndrome, myelitis, vasculitis, cholangitis sclerosing, hypoparathyroidism, arthritis, haemophagocytic lymphohistiocytosis, optic neuritis, gastritis, haemolytic anaemia, exocrine pancreatic insufficiency, pericarditis) and infusion reactions. The number of participants with an AEOSI was reported.

Time frame:
Up to approximately 66.5 months
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event of Special Interest (AEOSI)
ParticipantsPembrolizumab 200 mg IV Q3W
Number of Participants With an Adverse Event of Special Interest (AEOSI)33

Adverse events

Collected over Up to approximately 66.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab 200 mg IV Q3W13/150 (8.7%)31/150 (20.7%)105/150 (70%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventPembrolizumab 200 mg IV Q3W
Pleural effusionRespiratory, thoracic and mediastinal disorders3/150
Cardiac tamponadeCardiac disorders2/150
DiarrhoeaGastrointestinal disorders2/150
Urinary tract infectionInfections and infestations2/150
Cerebrovascular accidentNervous system disorders2/150
DyspnoeaRespiratory, thoracic and mediastinal disorders2/150
Cardiopulmonary failureCardiac disorders1/150
Abdominal painGastrointestinal disorders1/150
Rectal prolapseGastrointestinal disorders1/150
AstheniaGeneral disorders1/150
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPembrolizumab 200 mg IV Q3W
HypothyroidismEndocrine disorders26/150
AnaemiaBlood and lymphatic system disorders19/150
ConstipationGastrointestinal disorders17/150
FatigueGeneral disorders17/150
VitiligoSkin and subcutaneous tissue disorders17/150
PyrexiaGeneral disorders15/150
Urinary tract infectionInfections and infestations15/150
CoughRespiratory, thoracic and mediastinal disorders15/150
VomitingGastrointestinal disorders11/150
ArthralgiaMusculoskeletal and connective tissue disorders11/150

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab 200 mg IV Q3W
Mean55.3 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab 200 mg IV Q3W
Female64
Male86
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab 200 mg IV Q3W
Hispanic or Latino0
Not Hispanic or Latino150
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab 200 mg IV Q3W
American Indian or Alaska Native0
Asian150
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • Nizam's Institute of Medical Sciences ( Site 0011)
    Hyderabad, Andhra Pradesh 500082, India
  • Artemis Health Institute ( Site 0007)
    Gurgaon, Haryana 122001, India
  • Tata Memorial Hospital [M] ( Site 0005)
    Mumbai, Maharashtra 400012, India
  • Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001)
    Mumbai, Maharashtra 400053, India
  • Deenanath Mangeshkar Hospital and Research Center ( Site 0009)
    Pune, Maharashtra 411004, India
  • All India Institute of Medical Sciences ( Site 0012)
    New Delhi, National Capital Territory of Delhi 110029, India
  • Indraprastha Apollo Hospitals ( Site 0008)
    New Delhi, National Capital Territory of Delhi 110076, India
  • Rajiv Gandhi Cancer Institute and Research Centre ( Site 0003)
    Delhi, 110085, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Aug 2024, 66 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2018
First posted
Oct 23, 2018
StartActual
Jan 31, 2019
Primary completionActual
Aug 21, 2024
CompletionActual
Aug 21, 2024
Results first posted
Aug 29, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03715205
Responsible party
Sponsor
First posted
Oct 23, 2018
Start date
Jan 31, 2019
Primary completion
Aug 21, 2024
Completion
Aug 21, 2024
Results posted
Aug 29, 2025
Last update
Aug 29, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion